
Beam Therapeutics Inc is a biotechnology business based in the US. Beam Therapeutics Inc shares (BEAM) are listed on the NASDAQ and all prices are listed in US Dollars. Beam Therapeutics Inc employs 507 staff and has a trailing 12-month revenue of around $60.9 million.
How to buy Beam Therapeutics Inc stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – BEAM. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
eToro
- Easy to use platform with $0 stock trading & no annual fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100
tastytrade
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+
Beam Therapeutics Inc stock price (NASDAQ: BEAM)
Use our graph to track the performance of BEAM stocks over time.Beam Therapeutics Inc shares at a glance
Latest market close | $30.62 |
---|---|
52-week range | $27.77 - $73.27 |
50-day moving average | $39.23 |
200-day moving average | $46.72 |
Wall St. target price | $71.62 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-4.10 |
Buy Beam Therapeutics Inc stocks from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Is it a good time to buy Beam Therapeutics Inc stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Beam Therapeutics Inc price performance over time
Historical closes compared with the close of $30.62 from 2023-03-31
1 week (2023-03-24) | 0.76% |
---|---|
1 month (2023-03-01) | -20.47% |
3 months (2022-12-30) | -21.71% |
6 months (2022-09-30) | -35.73% |
1 year (2022-03-29) | -50.64% |
---|---|
2 years (2021-04-01) | -61.60% |
3 years (2020-04-01) | 89.95% |
5 years (2018-03-28) | N/A |
Beam Therapeutics Inc financials
Revenue TTM | $60.9 million |
---|---|
Gross profit TTM | $-250,674,000 |
Return on assets TTM | -15.02% |
Return on equity TTM | -33.35% |
Profit margin | 0% |
Book value | $10.54 |
Market capitalisation | $2.2 billion |
TTM: trailing 12 months
Beam Therapeutics Inc share dividends
We're not expecting Beam Therapeutics Inc to pay a dividend over the next 12 months.
Beam Therapeutics Inc share price volatility
Over the last 12 months, Beam Therapeutics Inc's shares have ranged in value from as little as $27.77 up to $73.27. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Beam Therapeutics Inc's is 1.6924. This would suggest that Beam Therapeutics Inc's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Beam Therapeutics Inc overview
Beam Therapeutics Inc. , a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency. The company has research collaboration agreement with Pfizer Inc. , focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc. , for cardiovascular disease treatments; Sana Biotechnology, Inc. , to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease; and the Institute of Molecular and Clinical Ophthalmology Basel for treatment of impaired vision and blindness.
Beam Therapeutics Inc in the news
11 Most Promising Gene Editing Stocks According to Analysts
Beam Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day
Beam Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day
Frequently asked questions
What percentage of Beam Therapeutics Inc is owned by insiders or institutions?Currently 1.931% of Beam Therapeutics Inc shares are held by insiders and 87.6% by institutions. How many people work for Beam Therapeutics Inc?
Latest data suggests 507 work at Beam Therapeutics Inc. When does the fiscal year end for Beam Therapeutics Inc?
Beam Therapeutics Inc's fiscal year ends in December. Where is Beam Therapeutics Inc based?
Beam Therapeutics Inc's address is: 238 Main Street, Cambridge, MA, United States, 02142 What is Beam Therapeutics Inc's ISIN number?
Beam Therapeutics Inc's international securities identification number is: US07373V1052
More guides on Finder
-
Best apps and platforms for ETF investing
The best trading apps come with low fees and are easy to use.
-
What happens if a brokerage firm fails?
Here’s what happens to your securities if your brokerage fails, and how your assets are protected by SIPC and FDIC.
-
How to Buy Gold Stocks
Learn about buying physical gold, plus stocks and ETFs, to learn how you can add gold exposure to your portfolio.
-
Silicon Valley Bank collapse: Which ETFs and stocks are impacted?
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
-
How to Buy Treasury Bills
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
-
SVB collapses: What does it mean for your portfolio?
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.
-
How to buy Vanguard VTI Total Stock Market ETF units
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
-
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
-
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
-
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
Ask an Expert